IMPACT OF PRIOR TREATMENT IN THE EFFICACY AND TOLERABILITY OF TIRBANIBULIN OINTMENT 1% FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES

Todd Schlesinger; Neal Bhatia; Brian Berman; Ayman Grada; Laura Padullés; Francisco Hernández; David Cutler; Mark Lebwohl

doi:10.25251/skin.6.supp.26

IMPACT OF PRIOR TREATMENT IN THE EFFICACY AND TOLERABILITY OF TIRBANIBULIN OINTMENT 1% FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES

Todd Schlesinger
, Neal Bhatia
, Brian Berman
, Ayman Grada
, Laura Padullés
, Francisco Hernández
, David Cutler
, Mark Lebwohl

Research output: Contribution to journal › Comment/debate

Original language	English
Journal	SKIN: Journal of Cutaneous Medicine
Volume	6
Issue number	2
DOIs	https://doi.org/10.25251/skin.6.supp.26
State	Published - 4 Mar 2022

Access to Document

10.25251/skin.6.supp.26

Cite this

@article{8f017227bf5d46c7931daaf885da00a1,

title = "IMPACT OF PRIOR TREATMENT IN THE EFFICACY AND TOLERABILITY OF TIRBANIBULIN OINTMENT 1\% FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES",

author = "Todd Schlesinger and Neal Bhatia and Brian Berman and Ayman Grada and Laura Padull{\'e}s and Francisco Hern{\'a}ndez and David Cutler and Mark Lebwohl",

note = "Funding Information: • Phase III studies were funded by Athenex. Post-hoc analysis/medical writing was funded by Almirall. • Writing support was provided by TFS HealthScience.",

year = "2022",

month = mar,

day = "4",

doi = "10.25251/skin.6.supp.26",

language = "English",

volume = "6",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "2",

}

TY - JOUR

T1 - IMPACT OF PRIOR TREATMENT IN THE EFFICACY AND TOLERABILITY OF TIRBANIBULIN OINTMENT 1% FOR ACTINIC KERATOSIS

T2 - POOLED RESULTS FROM TWO PHASE 3 STUDIES

AU - Schlesinger, Todd

AU - Bhatia, Neal

AU - Berman, Brian

AU - Grada, Ayman

AU - Padullés, Laura

AU - Hernández, Francisco

AU - Cutler, David

AU - Lebwohl, Mark

N1 - Funding Information: • Phase III studies were funded by Athenex. Post-hoc analysis/medical writing was funded by Almirall. • Writing support was provided by TFS HealthScience.

PY - 2022/3/4

Y1 - 2022/3/4

UR - https://www.scopus.com/pages/publications/85136246631

U2 - 10.25251/skin.6.supp.26

DO - 10.25251/skin.6.supp.26

M3 - Comment/debate

AN - SCOPUS:85136246631

SN - 2574-1624

VL - 6

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -